Helicobacter pylori-associated ulcer bleeding: Should we test for eradication after treatment?

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2005, Pages 529-537

  Pohl, H ^a,b,d   Finlayson, S R G ^a,b   Sonnenberg, A ^c   Robertson, D J ^a  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ANTIBIOTIC THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; ERADICATION THERAPY; FOLLOW UP; HEALTH CARE COST; HELICOBACTER PYLORI; MEDICAL DECISION MAKING; MONTE CARLO METHOD; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; FAMILY PRACTICE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PEPTIC ULCER HEMORRHAGE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE;

EID: 25444512123     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02569.x     Document Type: Article

References (34)

1. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331: 717-27.
2. Rockall TA, Logan RF, Devlin HB, Northfield TC. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1995; 346: 346-50.
3. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90: 206-10.
4. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc 1990; 36 (Suppl. 5): S8-13.
5. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002; 97: 2540-9.
6. Gisbert JP, Pajares JM. Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication? Scand J Gastroenterol 2003; 38: 2-9.
7. Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage [see comment]. Gastrointest Endosc 1995; 41: 5-7.
8. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease [see comment]. Gastrointest Endosc 1995; 41: 1-4.
9. Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 1996; 91: 1549-52.
10. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42.
11. Lai KC, Hui WM, Wong WM, et al. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - a long-term randomized, controlled study. Am J Gastroenterol 2000; 95: 2225-32.
12. Riemann JF, Schilling D, Schauwecker P, et al. Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding. Gastrointest Endosc 1997; 46: 299-304.
13. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19-23.
14. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004; 2: CD004062.
15. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330-8.
16. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-9.
17. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
18. Arkkila PE, Seppala K, Kosunen TU, et al. Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer. Am J Gastroenterol 2003; 98: 2149-56.
19. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700.
20. Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002; 97: 857-60.
21. Ohmann C, Imhof M, Roher HD. Trends in peptic ulcer bleeding and surgical treatment. World J Surg 2000; 24: 284-93.
22. Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D. Endoscopic hemostasis. An effective therapy for bleeding peptic ulcers. JAMA 1990; 264: 494-9.
23. Schoenberg MH. Surgical therapy for peptic ulcer and nonvariceal bleeding. Langenbecks Arch Surg 2001; 386: 98-103.
24. Center for Disease Control. Life Table 2001. Available at: http://www.cdc/nchs/data/dvs/lt2001.pdf
25. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997; 44: 545-55.
26. Kerridge RK, Glasziou PP, Hillman KM. The use of 'quality-adjusted life years' (QALYs) to evaluate treatment in intensive care. Anaesth Intensive Care 1995; 23: 322-31.
27. Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112: 1078-86.
28. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 559-78.
29. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997; 92: 614-20.
30. Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 2001; 15: 1067-76.
31. Vaira D, Gatta L, Ricci C, Miglioli M. Diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 (s1): 16-23.
32. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48: 287-9.
33. Thijs JC, van Zwei AA, Thijs WJ, et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard [see comment]. Am J Gastroenterol 1996; 91: 2125-9.
34. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection [see comment]. Gastroenterology 1995; 109: 136-41.